GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Cost of Goods Sold

Kintor Pharmaceutical (HKSE:09939) Cost of Goods Sold : HK$46.19 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Cost of Goods Sold?

Kintor Pharmaceutical's cost of goods sold for the six months ended in Dec. 2023 was HK$46.19 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was HK$46.19 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kintor Pharmaceutical's Gross Margin % for the six months ended in Dec. 2023 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover. Kintor Pharmaceutical's Inventory Turnover for the six months ended in Dec. 2023 was 0.14.


Kintor Pharmaceutical Cost of Goods Sold Historical Data

The historical data trend for Kintor Pharmaceutical's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Cost of Goods Sold Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial - - - - 46.19

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - 46.19

Kintor Pharmaceutical Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$46.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintor Pharmaceutical  (HKSE:09939) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kintor Pharmaceutical's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 46.189) / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Kintor Pharmaceutical's Inventory Turnover for the six months ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Kintor Pharmaceutical Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical (HKSE:09939) Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines